Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases
Authors:
Abstract
No abstract availableKeywords
This publication has 133 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Internal radiotherapy of painful bone metastasesMethods, 2011
- Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliationNuclear Medicine and Biology, 2011
- Towards translation of 212Pb as a clinical therapeutic; getting the lead in!Dalton Transactions, 2011
- Therapeutic Radionuclides: Biophysical and Radiobiologic PrinciplesSeminars in Nuclear Medicine, 2008
- Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bonesNuclear Medicine and Biology, 2007
- Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon modelNuclear Medicine and Biology, 1996
- In vivo distributions of some component fractions of Tc(NaBH4)-HEDP mixtures separated by anion exchange high performance liquid chromatographyThe International Journal of Applied Radiation and Isotopes, 1982
- Preparation of 186Re-Perrhenate for nuclear medical purposesThe International Journal of Applied Radiation and Isotopes, 1982
- Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasmsThe International Journal of Applied Radiation and Isotopes, 1979